bioRxivCell Biology
SF3B1 promotes tumor malignancy through splicing-independent co-activation of HIF1α
P. Simmler, C. Cortijo, L. M. Koch, P. Galliker, M. Schaefer, S. Angori, H. A. Bolck, C. Mueller, A. Vukolic, P. Mirtschink, Y. Christinat, N. R. Davidson, K.-V. Lehmann, G. Pellegrini, C. Pauli, D. Lenggenhager, I. Guccini, T. Ringel, C. Hirt, G. Raetsch, H. Moch, M. Stoffel, G. Schwank
Abstract
Mutations in the splicing factor SF3B1 are frequently occurring in various cancers and drive tumor progression through the activation of cryptic splice sites in multiple genes. Recent studies also demonstrate a positive correlation between expression levels of wildtype SF3B1 and tumor malignancy, but underlying mechanisms remain elusive. Here, we report that SF3B1 acts as an activator of HIF signaling through a splicing-independent mechanism. We demonstrate that SF3B1 forms a heterotrimer with HIF1 and HIF1{beta}, facilitating binding of the HIF1 complex to hypoxia response elements (HREs) to activate target gene expression. We further validate the relevance of this mechanism for tumor progression. Monoallelic deletion of Sf3b1 impedes formation and progression of hypoxic pancreatic cancer via impaired HIF signaling, but is well tolerated in normoxic chromophobe renal cell carcinoma. Our work uncovers an essential role of SF3B1 in HIF1 signaling, providing a causal link between high SF3B1 expression and aggressiveness of solid tumors.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SET1B drives sustained HIF activity and disease progression in clear cell renal cell carcinoma.
Brian M. Ortmann, Tekle Pauzaite, … James A. Nathan·Cancer ResearchPeer-reviewed·Apr 6, 2026
- Mutant SF3B1 promotes PDAC malignancy through TGF-β resistance
P. Simmler, T. Mengis, … G. Schwank·bioRxiv·Jun 16, 2022
- Non-canonical HIF-1 stabilization is essential for intestinal tumorigenesis
N. Rohwer, S. Jumpertz, … T. Cramer·bioRxiv·Feb 28, 2018
- Chemokine Receptor 1 and its associated immune pathway are downregulated in SF3B1MT blood and non-blood cancers
Mahtab Dastpak, Hyunmin Kim, … Robin Reed·bioRxiv·Mar 31, 2022
- SF3B1K700E rewires splicing of cell-cycle regulators
Mai Baker, Eden Engal, … Maayan Salton·RNAPeer-reviewed·Dec 24, 2025
- HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma
J. Contenti, Y. Guo, … N. M. Mazure·bioRxiv·Oct 17, 2023